

Curriculum Vitae
Dr. med. Jobst Röhmel

d.o.b. February 2nd 1978, in Berlin, Germany

University Education

2015 – Doctorate in Medicine (magna cum laude): Hypersensitivity to parenteral antibiotics in cystic fibrosis

2000–2006 – Studies of Medicine, Charité – Universitätsmedizin Berlin, Universidad de Barcelona, McGill University

Scientific and Clinical Career

Since 2025 - Founder and Head of outpatient clinic for Bronchiectasis and Rare Lung Diseases

Since 2025 – Senior Physician, Pneumology, Charité

Since 2024 – Specialist qualification in Allergology

2021 – 2025 - Senior Physician, Pediatric Pneumology, Charité

2017–2021 – Consultant Physician, Pediatric Pneumology

Since 2017 - Specialist qualification, Pediatric Pneumology

2015 - 2025 – Founder and Head of PCD outpatient clinic

Since 2013 – Board-certified Pediatrician

2007–2013 – Residency in Pediatrics

2007 – Research Fellow, University of Calgary

Current Positions

Since 2025 - Founder and Head of outpatient clinic for Bronchiectasis and Rare Lung Diseases

Since 2025 – Senior Physician, Pneumology, Charité

Since 2023 - Associate Principal Investigator, DZL

Additional Qualifications

Board certifications in Pediatric Pneumology and Allergology

Certification in Genetic Counseling

Extensive experience in AMG clinical trials (Phase I–III), GCP-certified

Research Focus

Monitoring of lung disease in rare lung diseases

Drug hypersensitivity reactions in rare lung diseases

Diagnostics of rare lung diseases

Collaborations

ERN-LUNG PCD Core

BEAT-PCD – Lead Work Package 3

University of Liverpool - Immunopharmacology

Memberships

GPP, DGPI, DGKJ, ERS, ECFS

Awards

2014 – Second Poster Prize, CF Conference

2010 – First Poster Prize, CF Conference

2003 – German National Academic Foundation Scholarship

Citation Record

Total citations: 4254; h-index: 23 (research gate 10.4.2026)

Top-10 selected Publications

Ruth M. Urbantat, Laura Behan, Sebastian Wisniewski, Joshua Gardner, Mirjam Stahl, Marcus A. Mall, Daniel Peckham, Dean J. Naisbitt, Jobst F. Roehmel. Immunogenic adverse events to CFTR modulators – an international survey. *Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society*, 2025.

Stahl M*, Roehmel J*, Eichinger M, Doellinger F, Naehrlich L, Kopp MV, Dittrich AM, Sommerburg O, Ray P, Maniktala A, Xu T, Conner S, Joshi A, Mascia M, Wielpütz MO, Mall MA. Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial. *Ann Am Thorac Soc*. 2024 Nov;21(11):1550-1559. Doi: 10.1513/AnnalsATS.202402-2010C. *shared first

Roehmel, J. F., Rohrbach, A., Staab, D., Mall, M. A., Ogese, M., Doerfler, F., & Naisbitt, D. (2023). Lymphocyte transformation tests predict delayed-type allergy to piperacillin/tazobactam in patients with cystic fibrosis. *Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society*, S1569-1993(23)01726-5. Advance online publication. <https://doi.org/10.1016/j.jcf.2023.12.003>

Stahl, M.*, Roehmel, J.*, Eichinger, M., Doellinger, F., Naehrlich, L., Kopp, M. V., Dittrich, A. M., Lee, C., Sommerburg, O., Tian, S., Xu, T., Wu, P., Joshi, A., Ray, P., Duncan, M. E., Wielpütz, M. O., & Mall, M. A. (2023). Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial. *Annals of the American Thoracic Society*, 20(8), 1144–1155. <https://doi.org/10.1513/AnnalsATS.202208-684OC>. *shared first

Loske, J*., Röhmel, J*., Lukassen, S., Stricker, S., Magalhães, V. G., Liebig, J., Chua, R. L., Thürmann, L., Messingschlager, M., Seegebarth, A., Timmermann, B., Klages, S., Ralser, M., Sawitzki, B., Sander, L. E., Corman, V. M., Conrad, C., Laudi, S., Binder, M., Trump, S., ... Lehmann, I. (2022). Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. *Nature biotechnology*, 40(3), 319–324. <https://doi.org/10.1038/s41587-021-01037-9>, * shared first

Roehmel, J. F.* , Doerfler, F.* J., Koerner-Rettberg, C., Brinkmann, F., Schlegtendal, A., Wetzke, M., Rudolf, I., Helms, S., Große-Onnebrink, J., Yu, Y., Nuesslein, T., Wojsyk-Banaszak, I., Becker, S., Eickmeier, O., Sommerburg, O., Omran, H., Stahl, M., & Mall, M. A. (2022). Comparison of the Lung Clearance Index in Preschool Children With Primary Ciliary Dyskinesia and Cystic Fibrosis. *Chest*, 162(3), 534–542. <https://doi.org/10.1016/j.chest.2022.02.052>. *shared first

Loyal, L., Braun, J., Henze, L., Kruse, B., Dingeldey, M., Reimer, U., Kern, F., Schwarz, T., Mangold, M., Unger, C., Dörfler, F., Kadler, S., Rosowski, J., Gürcan, K., Uyar-Aydin, Z., Frentsch, M., Kurth, F., Schnatbaum, K., Eckey, M., Hippenstiel, S., ...Lauster R.#, Lachman N.#, Sander. I.#, Corman V. #, Röhmel, J.#, Meyer-Arndt, L.#, Thiel, A.#, Giesecke-Thiel, C.# (2021). Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. *Science (New York, N.Y.)*, 374(6564), eabh1823. <https://doi.org/10.1126/science.abh1823>. # shared last

Roehmel, J., Specht, P., Staab, D., Schwarz, C., Salama, A., & Mayer, B. (2019). Risk of piperacillin-induced hemolytic anemia in patients with cystic fibrosis and antipseudomonal treatment: a prospective observational study. *Transfusion*, 59(12), 3746–3754. <https://doi.org/10.1111/trf.15591>

Schwarz, C., Brandt, C., Whitaker, P., Sutharsan, S., Skopnik, H., Gartner, S., Smazny, C., & Röhmel, J. F. (2018). Invasive Pulmonary Fungal Infections in Cystic Fibrosis. *Mycopathologia*, 183(1), 33–43. <https://doi.org/10.1007/s11046-017-0199-4>

Roehmel, J. F., Schwarz, C., Mehl, A., Stock, P., & Staab, D. (2014). Hypersensitivity to antibiotics in patients with cystic fibrosis. *Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society*, 13(2), 205–211. <https://doi.org/10.1016/j.jcf.2013.10.002>